/
CNCR
$9.02+$0.14 (+1.58%)prev close
Change$-21.63
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Asset Management
Loncar Cancer Immunotherapy ETF
This exchange-traded fund tracks an index primarily consisting of common stock from roughly 30 pharmaceutical or biotechnology companies. These firms are handpicked by the index provider due to their strong emphasis on creating innovative drugs that harness the human body's natural immune defenses to combat cancer. The fund's advisor aims to allocate all, or nearly all, of its capital into the underlying securities and American Depositary Receipts (ADRs) that comprise this benchmark index. A minimum of 80% of the fund's overall holdings will consistently be directed towards these specific index components. Notably, this fund operates as a non-diversified investment vehicle.
- IPO / List date
- Oct 14, 2015
- HQ
- US
Held by traders on TradeandTell
No one on the platform currently holds CNCR.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CNCR as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CNCR yet.
